GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rigel Pharmaceuticals Inc (NAS:RIGL) » Definitions » E10

Rigel Pharmaceuticals (Rigel Pharmaceuticals) E10 : $-0.55 (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Rigel Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Rigel Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was $-0.050. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.55 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was 13.00% per year. During the past 5 years, the average E10 Growth Rate was 9.20% per year. During the past 10 years, the average E10 Growth Rate was 12.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Rigel Pharmaceuticals was 67.60% per year. The lowest was 3.70% per year. And the median was 14.30% per year.

As of today (2024-05-24), Rigel Pharmaceuticals's current stock price is $0.9031. Rigel Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 was $-0.55. Rigel Pharmaceuticals's Shiller PE Ratio of today is .


Rigel Pharmaceuticals E10 Historical Data

The historical data trend for Rigel Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rigel Pharmaceuticals E10 Chart

Rigel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.74 -0.85 -0.75 -0.66 -0.56

Rigel Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.64 -0.62 -0.59 -0.56 -0.55

Competitive Comparison of Rigel Pharmaceuticals's E10

For the Biotechnology subindustry, Rigel Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rigel Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's Shiller PE Ratio falls into.



Rigel Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Rigel Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.05/131.7762*131.7762
=-0.050

Current CPI (Mar. 2024) = 131.7762.

Rigel Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201406 -0.290 100.560 -0.380
201409 -0.240 100.428 -0.315
201412 -0.250 99.070 -0.333
201503 -0.210 99.621 -0.278
201506 -0.160 100.684 -0.209
201509 -0.080 100.392 -0.105
201512 -0.140 99.792 -0.185
201603 -0.190 100.470 -0.249
201606 -0.150 101.688 -0.194
201609 -0.240 101.861 -0.310
201612 -0.160 101.863 -0.207
201703 -0.130 102.862 -0.167
201706 -0.160 103.349 -0.204
201709 -0.140 104.136 -0.177
201712 -0.180 104.011 -0.228
201803 -0.170 105.290 -0.213
201806 -0.160 106.317 -0.198
201809 -0.140 106.507 -0.173
201812 0.020 105.998 0.025
201903 -0.110 107.251 -0.135
201906 -0.120 108.070 -0.146
201909 -0.070 108.329 -0.085
201912 -0.100 108.420 -0.122
202003 0.130 108.902 0.157
202006 -0.100 108.767 -0.121
202009 -0.080 109.815 -0.096
202012 -0.110 109.897 -0.132
202103 0.220 111.754 0.259
202106 -0.080 114.631 -0.092
202109 -0.120 115.734 -0.137
202112 -0.130 117.630 -0.146
202203 -0.160 121.301 -0.174
202206 -0.080 125.017 -0.084
202209 -0.110 125.227 -0.116
202212 0.010 125.222 0.011
202303 -0.080 127.348 -0.083
202306 -0.040 128.729 -0.041
202309 -0.030 129.860 -0.030
202312 0.010 129.419 0.010
202403 -0.050 131.776 -0.050

Add all the adjusted EPS together and divide 10 will get our e10.


Rigel Pharmaceuticals  (NAS:RIGL) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Rigel Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Rigel Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Rigel Pharmaceuticals (Rigel Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Executives
Raul R Rodriguez officer: Sr VP of Bus Dev and Com Ops 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA 94080
David A Santos officer: EVP, Chief Commercial Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Wolfgang Dummer officer: EVP & CMO 5491 OPTICAL CT., SAN JOSE CA 95138
Dean L Schorno officer: EVP & Chief Financial Officer 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Raymond J. Furey officer: EVP, GC & Corp Sec 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807
Alison L. Hannah director 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Gary A Lyons director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Brian L. Kotzin director RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA 94060
Kamil Ali-jackson director C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
Jane Wasman director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Nelson Cabatuan officer: Principal Accounting Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Anne-marie Duliege officer: Chief Medical Officer 4001 MIRANDA AVENUE, PALO ALTO CA 94304
Mayer Eldon C. Iii officer: EVP & Chief Commercial Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Stacy Markel officer: EVP Human Resources RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080